Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
yes that has been on my watchlist for 2017. could be starter shares there for me. same with ARRY considering what they released tonight, could be a huge buy-in op tomorrow we just don't know at the moment
Jess and Vid, yes I fully agree with this regarding the closest competitor. Aurinia is dealing with something that could, I say could cuz we have to remain within reason, become the standard that fills in the void of an actual unmet need in a global condition.
Awesome. Nice to see you here
That's significant changes. Very nice input may TC recover to that degree!
Amen amen
I'm counting on having faith in that transparency as we are all allowing some flexibility after Glickman clearly stated at a recent fireside chat that he is seeking non-dilutive financing. Don't know what happened there however if he is committed to shareholders and patients as stated in that talk then this dip will be well worth it We all understand the perks to this massive fund raising for the pipeline
Exactly. If you can raise the funds why not get as much as you can.
good stuff Vid. I actually agree with Adam F's article that was published a few hours ago. While he never made any sense judging the success of Ariad's pipe interest he is making sound points with the successful funds raised yesterday by AUPH management and their intent not to please day traders but committed shareholder and stakeholders and patients
wait is this AMP from the Ariad board? the way you signed your name reminds me of a poster over there who I enjoyed reading. anyway GLTA
wise words!
I'm growing very confident that this ultimately won't be a long term dip. Though Glickman did mention he was seeking non-dilutive financing, I'm willing to accept this as the funds are there and then some for ph3 with no partners to split future profits which is a plus. I wouldn't be surprised if the company unleashes a series of PR's starting with the Aurion data and we rebound back into the $9-$10 and beyond
the old BR is back!!
this isn't dropping anywhere near my limit buy level.
I'm adding tomorrow for sure
another eagle eye call from Vid. they do the offering today, have the funds for ph3 and will rebound, won't have to divy up $ with partner
absolutely agree AKAO is a great example of what is possible. thanks for sharing
great post TC. Vid is the man. this celebratory dinner/party is a great idea
for all you pre-crash ariad old timers who started positions in this company congrats. After those years you all deserve less of a slog. I would love to know what is causing this parabolic activity. We all have our ideas as Vid has stated, undervalued mk cap, great science hitting the radar, etc. but still can anyone remember another example of such daily strength? GLTA
haha I enjoyed these posts. this lift is epic. watching the volume spin up is mesmerizing for sure.
denner would be a great advisor on this project for reasons I had mentioned in this mornings post about avoiding a premature sale. Mind you Glickman isn't a spring chicken in the buyout category either. In fact one of the first things noted was the buyout backgrounds of many of the management team over there at AUPH. enjoy the day and the ride folks
agreed vid. impressive
Adam F admitted he was "dead wrong" on Ariad the morning of the buyout announcement after being called out on Twitter. Days earlier he had published his biotech winners/losers year in review article. he left ariad as a "undecided" because though it outperformed his expectations he was still right that it wasn't sold in 2016. (meaning no one wanted it) then we know what happened 1/09/17. So he did admit he was wrong, however if would have been more appropriate to actually publish something to the masses that he was dead wrong. He did write that Takeda overpaid for the company. lol
But enough about Ariad regarding Aurinia really hope an early buyout doesn't occur here. the recent volume and activity as well as Glickman's aggressive marketing stance have been awesome but if the company sells soon it would be unfortunate as we all know the deep value that could be generated with a fully matured voclosporin.
Imagine what Denner would have received for selling ariad with only ponatinib and a very young brigatinib. I remember Meg Tirrell interviewing him during Berger's tenure, Denner was superbullish on pona and had little to elaborate on brig and that there wasn't a rush to put the company on a flash sale and to be very bullish on the drugs but to be patient. Well that patience turned into a clearer bullish picture on Brigatinib as well as incredible shareholder value return
Now that we have seen that 48week data Aurinia is just getting started!
Each day the shorts fall further. Today we see more blue sky breakout very very high 5 minute volume.
I see now, I was looking at another cell of the chart. I bet denner wishes he had the rest of those shares this morning!
Is Denner and Sarissa still on board here? according to this link Sarissa unloaded all shares reported in Feb?
https://fintel.io/so/us/apri
Apricus Biosciences Announces Sale of Ex-U.S. Vitaros Assets and Rights to Ferring Pharmaceuticals
http://ir.apricusbio.com/mobile.view?c=118007&v=203&d=1&id=2252612
Lmao. Always funny TC
Yes indeed Dew however my comment was referring to the elaboration on:
(from PR)
-----(Additional results to be presented today include:
Ammonia reduction correlates with clinical improvement, p=0.0006;
Dose proportional response and pharmacokinetic data indicate some patients were under-dosed;
Earlier timing of drug administration and efficacy assessment is important:
- Patients who improve within 48 hours are discharged earlier than patients who do not improve within 48 hours;
- Patients on OCR-002 are more likely to respond within 48 hours compared to placebo, p=0.026;
Pre-defined measures of improvement were statistically significant: ammonia reduction, p=0.017 and Physician overall evaluation, p= 0.026;
OCR-002 demonstrated improvement in the Model for End-Stage Liver Disease (MELD) scores, p=0.051; and
OCR-002 showed improvement in renal function as measured by the change from baseline in Blood Urea Nitrogen (BUN) levels, p=0.04---)
potentially good news. they halt/unhalt the stock then make everyone wait till 11:20am for details at Cowen. Should be a wild session up to then
Ocera is up at 11:20am et at Cowen
http://ir.ocerainc.com/releasedetail.cfm?ReleaseID=1016492
OCRX halted until 8:35am.
will report additional ‘encouraging results’ from its Phase 2b STOP-HE study of intravenous OCR-002 in hospitalized patients with Hepatic Encephalopathy at the Cowen and Company 37th Annual Healthcare Conference today.
encouraging? TBD
congrats TIV.
ride? more like a few G's from the Blue Angels!! :)
yeah thats how I feel...I was stoked as it blew past the early 5.75 resistance it was showing before all this. folks are very concerned when it relaxes to 6.80 from 7.00. lol
congrats! its been an incredible day and I won't be shocked one bit if we are reading another solid PR at 4pm
beast mode is an understatement here. Ludicrous Speed
as I write this the stock is on an absolute tear,. hopefully this cools off a bit as it is very unusual. Leak? PR at 4pm? fun to watch but acting insane Good luck longs
I have definitely picked up on Glickman's aggressive posture with marketing the accomplishments of the science. Perhaps that was a major difference with the recent outgoing CEO. My feeling is that Glickman wants to sell this company sooner than later and move on to his next project. Im not saying he won't show patience in fielding offers and receiving strong premiums if accepted. I think he ultimately sees this company getting taken out between $25-$30 perhaps late in ph3. The question is will he and the board also consider offers in the next couple of months for $15-17. still significant premiums considering their respective cost bases
Vertex to Acquire CTP-656 from Concert Pharmaceuticals for the Treatment of Cystic Fibrosis
http://ir.concertpharma.com/releasedetail.cfm?ReleaseID=1015936
FBR capital sees Aurinia as a potential takeout target in this environment of shifting FDA and tax easing administration